Corbus Pharmaceuticals Holdings (STU:3371) 3-Year EBITDA Growth Rate : 39.60% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Corbus Pharmaceuticals Holdings 3-Year EBITDA Growth Rate?

Corbus Pharmaceuticals Holdings's EBITDA per Share for the three months ended in Dec. 2023 was €-2.19.

During the past 3 years, the average EBITDA Per Share Growth Rate was 39.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 26.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -21.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Corbus Pharmaceuticals Holdings was 39.60% per year. The lowest was -181.90% per year. And the median was -34.45% per year.

Competitive Comparison of Corbus Pharmaceuticals Holdings's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corbus Pharmaceuticals Holdings's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's 3-Year EBITDA Growth Rate falls into.

Corbus Pharmaceuticals Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Corbus Pharmaceuticals Holdings (STU:3371) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Corbus Pharmaceuticals Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Corbus Pharmaceuticals Holdings (STU:3371) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (STU:3371) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CRBP:USA

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.

Corbus Pharmaceuticals Holdings (STU:3371) Headlines

No Headlines